Angel Invest Boston

Invest Alongside Boston's Top Angels: Our Investment Syndicates How to fund scrappy biotech startups is foremost on Jeff Behrens’ mind. He was CEO if a startup that raised $20 million in funding but not one cent from VCs. An invaluable interview for anyone thinking of starting or investing in a life science company. Highlights include: Jeff Behrens Studied Philosophy at Harvard but Stumbled Upon Entrepreneurship: Renaissance Man for the 21st Century MIT/Harvard Medical School Collaboration, HST, is Discussed Siamab Therapeutics Siamab Pursues Therapies Based on the Work of Ajit Varki on the Weird Sugars on the Surface of Cancer Cells Siamab Did Not Go the VC Route, I Took a Scrappier Approach to Funding from Other Sources Ovarian or Pancreatic Cancers Are Tough to Fight; Siamab Targeted them Based on the Unique Sugars on the Outside of the Cancer Cells Creating Lethal Molecules that Attack only the Cancer Cells Standard Chemotherapy Is a Carpet-Bombing Approach, Doing Harm to Healthy Cells Jeff Behrens Has S